tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Shivaswamy V et al. Tacrolimus and sirolimus induce reproductive abnormalities in female rats. 2011 Transplantation pmid:21508897
Pech T et al. Combination therapy of tacrolimus and infliximab reduces inflammatory response and dysmotility in experimental small bowel transplantation in rats. 2012 Transplantation pmid:22167049
Charlton M et al. Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. 2017 Transplantation pmid:28817434
Egawa H et al. FK506 conversion therapy in pediatric liver transplantation. 1994 Transplantation pmid:7513911
Cvetkovic M et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. 1994 Transplantation pmid:7513912
Pirsch JD Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. 1999 Transplantation pmid:10551653
Singh N et al. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. 2000 Transplantation pmid:10708096
Zoppo A et al. Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. 1999 Transplantation pmid:10551656
Haririan A et al. Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. 2003 Transplantation pmid:12717201
Ciancio G et al. Randomized trial of three induction antibodies in kidney transplantation: long-term results. 2014 Transplantation pmid:24477186
Gonwa T et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. 2003 Transplantation pmid:12717205
Tzakis AG et al. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. 2003 Transplantation pmid:12717207
Rush DN et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. 2009 Transplantation pmid:19935461
Khanna A et al. Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow. 1998 Transplantation pmid:9500620
Firdaous I et al. Pediatric intravenous FK506--how much are we really infusing? 1994 Transplantation pmid:7517079
Manez R et al. Rejection and hepatitis in liver transplants. 1994 Transplantation pmid:7517080
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Sindhi R et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. 2001 Transplantation pmid:11571449
Deuse T et al. The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent. 2004 Transplantation pmid:15084926
Timmermann W et al. Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. 1999 Transplantation pmid:10401762
Gupta A et al. Elevated myeloid: plasmacytoid dendritic cell ratio associates with late, but not early, liver rejection in children induced with rabbit anti-human thymocyte globulin. 2009 Transplantation pmid:19696644
Gerlach UA et al. Intragraft and Systemic Immune Parameters Discriminating Between Rejection and Long-Term Graft Function in a Preclinical Model of Intestinal Transplantation. 2017 Transplantation pmid:27607529
Dhar DK et al. Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. 1993 Transplantation pmid:7506456
Fabrega AJ et al. Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. 1993 Transplantation pmid:7506458
Jain A et al. FK506 and pregnancy in liver transplant patients. 1993 Transplantation pmid:7506459
Koomans HA and Ligtenberg G Mechanisms and consequences of arterial hypertension after renal transplantation. 2001 Transplantation pmid:11585243
Burke MD et al. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. 1990 Transplantation pmid:1700507
Trimarchi HM et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. 1999 Transplantation pmid:10071024
Chisholm MA et al. Renal transplant patient compliance with free immunosuppressive medications. 2000 Transplantation pmid:11063348
Naesens M et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. 2006 Transplantation pmid:17060857
Suzuki S et al. Pure red cell aplasia induced by FK506. 1996 Transplantation pmid:8607191
Kaufman DB et al. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. 1999 Transplantation pmid:10071032
Dominguez J et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. 2000 Transplantation pmid:11063349
Conrotto D et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. 2006 Transplantation pmid:17060865
Khanna A et al. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. 1999 Transplantation pmid:10071036
Kessler M et al. A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. 1999 Transplantation pmid:10071045
Rostaing L et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. 2005 Transplantation pmid:15818323
Jiang H et al. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. 2002 Transplantation pmid:12085006
Grudé P et al. MDR1 gene expression in peripheral blood mononuclear cells after liver transplantation. 2002 Transplantation pmid:12085008
Moutabarrik A et al. FK506-induced kidney tubular cell injury. 1992 Transplantation pmid:1281562
Tzakis AG et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. 2004 Transplantation pmid:15114087
Lang T et al. Cholic acid synthesis is reduced in pediatric liver recipients during graft dysfunction due to ischemic injury and allograft rejection. 1997 Transplantation pmid:9415561
Stojanovic J et al. Immune Desensitization Allows Pediatric Blood Group Incompatible Kidney Transplantation. 2017 Transplantation pmid:27463537
Bechstein WO et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. 2004 Transplantation pmid:15114089
Lo A et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. 2004 Transplantation pmid:15114090
Talbot D et al. Alopecia as a consequence of tacrolimus therapy in renal transplantation? 1997 Transplantation pmid:9415574
Jin S et al. Effect of tacrolimus on the expression of macrophage scavenger and nuclear hormone receptors in THP-1-derived human macrophages. 2004 Transplantation pmid:15114099
Shoker A et al. Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. 2000 Transplantation pmid:10949194
Straatman LP and Coles JG Pediatric utilization of rapamycin for severe cardiac allograft rejection. 2000 Transplantation pmid:10949201
Levitsky J et al. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. 2011 Transplantation pmid:21239962
Tokita D et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. 2008 Transplantation pmid:18301333
Gruessner RW and Sharp HL Living-related intestinal transplantation: first report of a standardized surgical technique. 1997 Transplantation pmid:9415566
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Chan K et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial. 2011 Transplantation pmid:21836540
Gujadhur A et al. CMV sinusitis in a HIV-negative renal transplant recipient. 2014 Transplantation pmid:24827770
Jain AB et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. 1998 Transplantation pmid:9846530
Qi S et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. 2000 Transplantation pmid:10798741
Borger P et al. Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. 2000 Transplantation pmid:10798763
Moffatt SD et al. STAT 6 up-regulation by FK506 in the presence of interleukin-4. 2000 Transplantation pmid:10798785
Riegersperger M et al. Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. 2013 Transplantation pmid:23594858
Poncelet AJ et al. Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus. 2008 Transplantation pmid:19077894
Uchida N et al. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. 2011 Transplantation pmid:21677598
Kovarik JM et al. Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. 2011 Transplantation pmid:21157403
Jugie M et al. Study of the impact of liver transplantation on the outcome of intestinal grafts in children. 2006 Transplantation pmid:16612274
Augustine JJ et al. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. 2006 Transplantation pmid:16612276
Paty BW et al. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. 2002 Transplantation pmid:11884930
Dell'Antonio G and Randhawa PS "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. 1999 Transplantation pmid:10030300
Wu MJ et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. 2011 Transplantation pmid:21912349
Vyas S et al. Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. 1999 Transplantation pmid:10030303
Song L et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. 2014 Transplantation pmid:24992357
Baran DA et al. Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. 2002 Transplantation pmid:12438960
Kasahara M et al. Role of HLA compatibility in pediatric living-related liver transplantation. 2002 Transplantation pmid:12438966
van Maarseveen EM et al. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. 2013 Transplantation pmid:23250333
Shivaswamy V et al. Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats. 2013 Transplantation pmid:23250335
Xu H et al. Simultaneous bone marrow and composite tissue transplantation in rats treated with nonmyeloablative conditioning promotes tolerance. 2013 Transplantation pmid:23250336
Hudnall SD Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A? 2002 Transplantation pmid:12369583
Ericzon BG et al. FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. 1992 Transplantation pmid:1384189
Paolillo JA et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 2001 Transplantation pmid:11213069
Molmenti EP et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. 2001 Transplantation pmid:11213072
Vanrenterghem Y et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. 2004 Transplantation pmid:15257032
Mourer JS et al. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients. 2013 Transplantation pmid:23715049
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Armitage JM et al. Preliminary experience with FK506 in thoracic transplantation. 1991 Transplantation pmid:1713363
Lorber MI et al. A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. 1991 Transplantation pmid:1713364
Deuse T et al. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. 2012 Transplantation pmid:22971540
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Jain A et al. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. 2011 Transplantation pmid:21378604
Cohen JB et al. Belatacept Compared With Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study. 2017 Transplantation pmid:27941427
Jordan ML et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. 1994 Transplantation pmid:7512293
Lauzurica R et al. Tacrolimus-associated severe bilateral corneal ulcer after renal transplantation. 2002 Transplantation pmid:11923710
Bolley R et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. 2002 Transplantation pmid:11923712
Kashu Y et al. The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. 1996 Transplantation pmid:8633382
Higgins RM et al. Conversion from tacrolimus to cyclosporin in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10919600
Yoshimura N et al. A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). 1996 Transplantation pmid:8633388
Puig I Marí JM et al. Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. 2000 Transplantation pmid:10919604
Zieliński A et al. Simultaneous pancreas-kidney transplant from living related donor: a single-center experience. 2003 Transplantation pmid:12923442
Erickson LM et al. Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. 2003 Transplantation pmid:12923448
Maluccio M et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. 2003 Transplantation pmid:12923450
Pascher A et al. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation. 2003 Transplantation pmid:12923454
Mayer AD et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. 1997 Transplantation pmid:9275110